Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,766 public trials 495 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Active, Not Recruiting

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

NCT06521567

Conditions
Adenocarcinoma, Astrocytoma, Brain Diseases, +56 more
Locations
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Iowa City, Iowa, United States
  • GSK Investigational Site Hackensack, New Jersey, United States
  • GSK Investigational Site Cincinnati, Ohio, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +26 more
Locations
  • GSK Investigational Site Goodyear, Arizona, United States
  • GSK Investigational Site Scottsdale, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
View all 89 locations
View Trial Details
Active, Not Recruiting

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

NCT04056247

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +23 more
Locations
  • Birmingham VAHCS Birmingham, Alabama, United States
  • Mayo Clinic Jacksonville, Florida, United States
  • University of Miami Miami, Florida, United States
  • Florida Cancer Specialist and Research Institute Orlando, Florida, United States
View all 41 locations
View Trial Details
Active, Not Recruiting

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

NCT04139902

Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, +11 more
Locations
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Intrathecal Double Checkpoint Inhibition

NCT05598853

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +25 more
Locations
  • University Hospital Zurich Zurich, Canton of Zurich, Switzerland
  • University Hospital Basel Basel, Switzerland
  • University Hospital Geneva Geneva, Switzerland
View Trial Details

Related conditions